IGM Biosciences, Inc. (IGMS) has seen a downfall of 19.86% in premarket. However, the last trading session closed at $49.84 with a decrease of 2.06%.
Clinical Data from IGM-2323 – What’s up?
On 11th December 2021, IGMS announced the clinical findings from its Phase 1 study that was meant to analyse IGM-2323. The stability, pharmacokinetics, and initial effectiveness of intravenous IGM-2323 in patients with advanced B cell malignancies were evaluated in this multicenter, open-label Phase 1 dosage escalation study. Moreover, 40 patients had been recruited and treated with increasing dosage levels of IGM-2323.
At least one dosage was given to each of the 40 patients, and their safety was assessed. There have been no dose-limiting toxicities (DLTs), no neurological adverse events (AEs), a low risk of cytokine release syndrome (CRS), and no participants were removed from the study because of an AE.
The research illustrates that IGM-2323 is incredibly active against multiple subtypes of relapsed/refractory non-lymphoma Hodgkin’s and shows an anti-inflammatory property with low rates of CRS, no CRS-associated neurodegeneration, and negligible neutropenia. Furthermore, the results of this Phase 1 research so far are positive, and the company is planning to look into the possibilities of this significant innovative medicine in these difficult-to-treat illness areas. Last but not least, patients with non-lymphoma Hodgkin’s require effective and well-tolerated therapies, and IGM-2323 may be a good fit to fill that gap.
Collaboration on Study of IgM and IgA Antibodies – Latest News
On 8th December 2021, IGMS reported that the company has an agreement with the Bill & Melinda Gates Foundation. This collaboration is meant to finance the development, manufacture, and testing of IgM and IgA antibodies for malaria prevention.
Malaria is one of the deadliest human illnesses in the underdeveloped world, despite recent advancements in prevention and treatment. According to the World Health Organization, there are about 200 million cases and 400,000 fatalities globally each year. Moreover, anti-CSP monoclonal antibodies have been found to be effective in preventing infection and sickness. Lastly, IgM and IgA antibodies directed against CSP may have greatly enhanced potency as a result of their multimeric shape, allowing them to provide advantages at lower dosages.
Third Quarter 2021 Results – How’s the quarter?
IGMS announced third quarter 2021 results on 4th November 2021. According to the report issued by the company, the cash and investments came out to be $265.6 million, $366.3 million less than that of December 31, 2020. Moreover, the R&D expenses were $34.2 million and G&A expenses totaled $10.0 million in the third quarter of 2021. Lastly, the company reported a net loss of $44.2 million.